Download PDF
Horm Metab Res 2001; 33(3): 167-169
DOI: 10.1055/s-2001-14932
Original Clinical

© Georg Thieme Verlag Stuttgart · New York

Effects of Amlodipine on Serum Levels of Adrenal Androgens and Insulin in Hypertensive Men with Obesity

H. Ueshiba, K. Tsuboi, Y. Miyachi
  • First Department of Internal Medicine, Toho University School of Medicine, Ohmori-Nishi, Ohta-Ku, Tokyo, Japan
Further Information

Publication History

Publication Date:
31 December 2001 (online)

Also available at
    Permissions and Reprints

We investigated the effects of the calcium channel blocker amlodipine besilate on serum levels of adrenal androgens and insulin in 20 men with essential hypertension and obesity (age: 51.9 ± 4.7 years, body mass index: 27.7 ± 1.5 kg/m2). All were treated with amlodipine besilate (Norvasc) for 3 months. Blood pressure, fasting plasma glucose (FPG), HbA1c and serum levels of insulin, dehydroepiandrosterone (DHEA), DHEA sulfate (DHEA-S), and lipids were measured before and after a 3-month period. In 10 patients, 75 g oral glucose tolerance test (75 g-OGTT) was also performed. Amlodipine besilate treatment 1) lowered the fasting serum insulin level and total serum insulin level during 75 g-OGTT and 2) increased serum DHEA and DHEA-S levels. No changes in fasting plasma glucose, HbA1c and serum lipids were observed during treatment. We conclude that amlodipine besilate improves insulin resistance and consequently increases serum DHEA and DHEA-S levels.

Key words:

Amlodipine - Dehydroepiandrosterone (DHEA) - Dehydroepiandrosterone Sulfate (DHEA-S) - Insulin - Hypertension - Obesity

References:

  • 1 Ferrannini E, Buzzigoli G, Bonadonna R, Giorico M A, Oleggini M, Graziadei L, Pedrinelli R, Grandi L, Bevilacqua S. Insulin resistance in essential hypertension.  N Engl J Med. 1987;  317 350-357
    CrossrefPubMedGoogle Scholar
  • 2 Serrano-Gotarredona J, Escobar-Morreale H F, Sancho J M, Garcia-Robles R. Insulin resistance, dehydroepiandrosterone sulfate and sex hormone-binding globulin in essential hypertension.  Horm Metab Res. 1998;  30 153-157
    PubMedGoogle Scholar
  • 3 Gordon G B, Bush D E, Weisman H F. Reduction of atherosclerosis by administration of dehydroepiandrosterone. A study in the hypercholesterolemic New Zealand white rabbit with aortic intimal injury.  J Clin Invest. 1988;  82 712-720
    PubMedGoogle Scholar
  • 4 Nestler J E, Barlascini C O, Clore J N, Blackard W G. Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men.  J Clin Endocrinol Metab. 1988;  66 57-61
    PubMedGoogle Scholar
  • 5 Coleman D L, Leiter E H, Schwizer R W. Therapeutic effects of dehydroepiandrosterone (DHEA) in diabetic mice.  Diabetes. 1982;  31 830-833
    CrossrefPubMedGoogle Scholar
  • 6 Nestler J E, Strauss J F. Insulin as an effector of human ovarian and adrenal steroid metabolism.  Endocrinol Metab Clin North Am. 1991;  20 807-823
    PubMedGoogle Scholar
  • 7 Smith S, Ravnikar V A, Barbieri R L. Androgen and insulin response to an oral glucose challenge in hyperandrogenic women.  Fertil Steril. 1987;  48 72-77
    PubMedGoogle Scholar
  • 8 Schriock E D, Buffington C K, Hubert G D, Kurtz B R, Kitabchi A E, Buster J E, Givens J R. Divergent correlations of circulating dehydroepiandrosterone sulfate and testosterone with insulin levels and insulin receptor binding.  J Clin Endocrinol Metab. 1988;  66 1329-1331
    PubMedGoogle Scholar
  • 9 Falcone T, Finegood D T, Fantus I G, Morris D. Androgen response to endogenous insulin secretion during the frequently sampled intravenous glucose tolerance test in normal and hyperandrogenic women.  J Clin Endocrinol Metab. 1990;  71 1653-1657
    PubMedGoogle Scholar
  • 10 Nestler J E, Clore J N, Blackard W G. Dehydroepiandrosterone: the “missing link” between hyperinsulinemia and atherosclerosis?.  FASEB J. 1992;  6 3073-3075
    PubMedGoogle Scholar
  • 11 Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.  N Engl J Med. 1989;  321 868-873
    CrossrefPubMedGoogle Scholar
  • 12 Beer N A, Jakubowicz D J, Beer R M, Arocha I R, Nestler J E. Effects of nitrendipine on glucose tolerance and serum insulin and dehydroepiandrosterone sulfate levels in insulin-resistant obese and hypertensive men.  J Clin Endocrinol Metab. 1993;  76 178-183
    CrossrefPubMedGoogle Scholar
  • 13 Beer N A, Jakubowicz D J, Beer R M, Nestler J E. The calcium channel blocker amlodipine raises serum dehydroepiandrosterone sulfate and androstenedione, but lowers serum cortisol, in insulin-resistant obese and hypertensive men.  J Clin Endocrinol Metab. 1993;  76 1464-1469
    CrossrefPubMedGoogle Scholar
  • 14 Pollare T, Lithell H, Selinus I, Berne C. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension.  Diabetologia. 1988;  31 415-420
    CrossrefPubMedGoogle Scholar
  • 15 Berne C, Pollare T, Lithell H. Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors.  Diabetes Care. 1991;  14 (Suppl 4) 39-47
    PubMedGoogle Scholar
  • 16 Baron A D, Brechtel G, Wallace P, Edelman S V. Rates and tissue sites of non-insulin- and insulin-mediated glucose uptake in humans.  Am J Physiol. 1988;  255 E769-774
    PubMedGoogle Scholar
  • 17 Draznin B, Sussman K E, Eckel R H, Kao M, Yost T, Sherman N A. Possible role of cytosolic free calcium concentrations in mediating insulin resistance of obesity and hyperinsulinemia.  J Clin Invest. 1988;  82 1848-1852
    PubMedGoogle Scholar

H. Ueshiba

First Department of Internal Medicine
Toho University School of Medicine

6-11-1 Ohmori-Nishi, Ohta-Ku
Tokyo, 143-0015
Japan


Phone: Phone:+ 81 (3) 3762-4151

Fax: Fax:+ 81 (3) 3763-8298

Email: E-mail:ueshiba@med.toho-u.ac.jp